Shionogi & Co., Ltd. has decided on the basic policy to absorb its wholly owned subsidiary Torii Pharmaceutical Co., Ltd. through a merger effective April 1, 2027.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4507","jir_company_name":"Shionogi & Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-20","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4507-20260220-01.pdf","jir_short_summary":"Shionogi & Co., Ltd. has decided on the basic policy to absorb its wholly owned subsidiary Torii Pharmaceutical Co., Ltd. through a merger effective April 1, 2027.","jir_summary":"### Overview of the M&A\nShionogi & Co., Ltd. resolved at the Board of Directors meeting on February 20, 2026, the basic policy to absorb its wholly owned subsidiary Torii Pharmaceutical Co., Ltd. through an absorption-type merger effective April 1, 2027. Torii Pharmaceutical became a wholly owned subsidiary on September 1, 2025, and this merger aims to strengthen collaboration between the two companies and maximize integration synergies. The merger will be conducted as an absorption-type merger, with Torii Pharmaceutical as the dissolved company, and there will be no issuance of new shares or allocation of cash.\n\n### Future Outlook and Impact\nAs this merger is between a parent company and its wholly owned subsidiary, the impact on Shionogi & Co., Ltd.'s consolidated performance is expected to be minimal. Detailed schedules concerning the merger will be disclosed as soon as they are decided. After the merger, there will be no changes to the trade name, location, representatives, business content, capital stock, or fiscal year-end.","jir_financial_highlights":"Revenue (Shionogi & Co., Ltd. Consolidated): 438,268 million JPY (Unknown)\nNet Sales (Torii Pharmaceutical Standalone): 60,426 million JPY (Unknown)\nOperating Income (Shionogi & Co., Ltd. Consolidated): 156,603 million JPY (Unknown)\nOperating Income (Torii Pharmaceutical Standalone): 6,798 million JPY (Unknown)\nNet Income Attributable to Owners of Parent (Shionogi & Co., Ltd. Consolidated): 170,435 million JPY (Unknown)\nNet Income (Torii Pharmaceutical Standalone): 5,042 million JPY (Unknown)\nCapital Stock (Shionogi & Co., Ltd.): 21,279 million JPY (Unknown)\nCapital Stock (Torii Pharmaceutical): 5,190 million JPY (Unknown)\nTotal Number of Issued Shares (Shionogi & Co., Ltd.): 889,632,195 shares (Unknown)\nTotal Number of Issued Shares (Torii Pharmaceutical): 6 shares (Unknown)","jir_category":"","jir_hashtags":"#ShionogiAndCoLtd, #corporate_restructuring, #JapaneseStocks","jir_key_figures":"Merger Effective Date: Scheduled April 1, 2027\nShionogi & Co., Ltd. Consolidated Revenue: 438,268 million JPY (Fiscal Year Ending March 2025)\nTorii Pharmaceutical Standalone Net Sales: 60,426 million JPY (Fiscal Year Ending December 2024)","jir_meta_title":"Shionogi to Absorb Torii Pharmaceutical on April 1, 2027 - Basic Policy Decision Announced","jir_meta_description":"Shionogi & Co., Ltd. has decided on a basic policy to absorb its wholly owned subsidiary Torii Pharmaceutical Co., Ltd. effective April 1, 2027. The merger aims to strengthen collaboration and maximize synergies between the two companies.","jir_og_title":"Shionogi Announces Basic Policy for Absorption-Type Merger with Torii Pharmaceutical","jir_og_description":"Shionogi & Co., Ltd. has resolved to absorb its wholly owned subsidiary Torii Pharmaceutical Co., Ltd. effective April 1, 2027. The merger's impact on business performance is expected to be minimal.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6919,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"corporate_restructuring","footnotes":""},"sector":[],"importance":[],"class_list":["post-30532","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n